Medicine
Pamidronate 90 mg/10 mL injection
Pamidronate 90 mg/10 mL injection is a generic prescription medicine for intravenous use, made by 2 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20 to 25°C (68 to 77°F).
Key facts
- Active ingredient (INN)
- Pamidronate
- Brand
- Sold under the generic name
- Strength
- 90 mg/10 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 10 mL
- Manufacturers
- HospiraMylan Institutional
- Origin register
- US FDA, United States
- Storage
- Store at 20 to 25°C (68 to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- M05BA03 Pamidronate
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 October 2005
- Identifiers
- RxCUI 1737449, 1737451, 1737453DailyMed set ID 9b6a9a3b-71c9-4dcb-b857-5d1de25c3a23, c2ca033e-fa5f-4141-b702-11f8b4303da1NDC 61703-326, 67457-446Application ANDA075841, ANDA078520
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-dose in 1 carton / 10 mL in 1 vial, single-dose | 61703-326-18 | Hospira | 1 October 2005 |
| 1 vial in 1 carton / 10 mL in 1 vial | 67457-446-10 | Mylan Institutional | 10 May 2011 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 31 October 1991 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Pamidronate
Clinical summary
Pamidronate is a bisphosphonate indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases, among other approved uses. It is available as injection for intravenous use. MedsAcross supplies Pamidronate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about PamidronateFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Pamidronate Disodium prescribing information (Hospira) · U.S. National Library of Medicine, DailyMed
Need Pamidronate 90 mg/10 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.